PriceTargets.com logo

TRxADE HEALTH - MEDS Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.97 As of 05/1/2024 06:27 PM ET
▲ +0.01 (0.17%)

This chart shows the closing price for MEDS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TRxADE HEALTH Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MEDS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MEDS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for TRxADE HEALTH in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.97.

This chart shows the closing price for MEDS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in TRxADE HEALTH. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2023Maxim GroupLower TargetBuy$37.50 ➝ $26.25Low
3/29/2022Maxim GroupLower Target$165.00 ➝ $105.00High
7/28/2021Maxim GroupReiterated RatingBuy$165.00Low
7/27/2021Colliers SecuritiesReiterated RatingBuy$120.00Low
7/2/2021Colliers SecuritiesReiterated RatingBuy$150.00Medium
3/30/2021Colliers SecuritiesReiterated RatingBuy$150.00High
2/26/2021Maxim GroupInitiated CoverageBuyHigh
12/3/2020National SecuritiesInitiated CoverageBuy$225.00High
6/10/2020Taglich BrothersReiterated RatingSpeculative BuyHigh
4/30/2020Dougherty & CoReiterated RatingBuy$180.00Low
(Data available from 5/1/2019 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/3/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
2/1/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/2/2024
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/1/2024
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2024

Current Sentiment

  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
TRxADE HEALTH logo
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which offers price transparency, purchasing capabilities, and other value-added services; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Lutz, Florida.
Read More

Today's Range

Now: $5.97
Low: $5.82
High: $6.18

50 Day Range

MA: $12.47
Low: $5.96
High: $33.90

52 Week Range

Now: $5.97
Low: $3.69
High: $44.56

Volume

2,374 shs

Average Volume

328,827 shs

Market Capitalization

$8.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

Frequently Asked Questions

What sell-side analysts currently cover shares of TRxADE HEALTH?

The following Wall Street analysts have issued reports on TRxADE HEALTH in the last year:
View the latest analyst ratings for MEDS.

What is the current price target for TRxADE HEALTH?

0 Wall Street analysts have set twelve-month price targets for TRxADE HEALTH in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for TRxADE HEALTH in the next year.
View the latest price targets for MEDS.

What is the current consensus analyst rating for TRxADE HEALTH?

TRxADE HEALTH currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MEDS.

What other companies compete with TRxADE HEALTH?

Other companies that are similar to TRxADE HEALTH include Cosmos Health, BIMI, eFFECTOR Therapeutics, NuCana and Precipio. Learn More about companies similar to TRxADE HEALTH.

How do I contact TRxADE HEALTH's investor relations team?

TRxADE HEALTH's physical mailing address is 3840 Land O' Lakes Blvd., Land O' Lakes FL, 34639. The company's listed phone number is (800) 261-0281 and its investor relations email address is [email protected]. The official website for TRxADE HEALTH is www.trxade.com. Learn More about contacing TRxADE HEALTH investor relations.